Literature DB >> 12142169

Brain-tumour drug resistance: the bare essentials.

Markus Bredel1, Josef Zentner.   

Abstract

Chemotherapy lacks efficacy in most histological types of primary human brain tumours and has, for most types, failed to improve outcome for patients. The unsatisfactory results with chemotherapeutic intervention in these cancers have been chiefly attributed to tumour-cell resistance. This review summarises some of the major molecular markers that, although neither exclusive for nor specific to brain tumours, have been associated with the formation of a chemoresistant phenotype. Elucidation of the cellular mechanisms involved in resistance regulation is needed for future progress in efficient approaches to selective modulation of drug resistance in these lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142169     DOI: 10.1016/s1470-2045(02)00786-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  26 in total

1.  Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Authors:  Dong Lan; Li Wang; Rongquan He; Jie Ma; Yehong Bin; Xiaojv Chi; Gang Chen; Zhengwen Cai
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

2.  Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.

Authors:  Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  NMR Biomed       Date:  2006-12       Impact factor: 4.044

3.  Gene expression profiles of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)-resistant C6 rat glioma cells.

Authors:  Takao Nakagawa; Toshihiko Kubota; Kazunori Ido; Takahiro Sakuma; Ken Matsuda
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

4.  Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Authors:  Kaijun Di; G Kenneth Lloyd; Vivek Abraham; Ann MacLaren; Francis J Burrows; Annick Desjardins; Mohit Trikha; Daniela A Bota
Journal:  Neuro Oncol       Date:  2015-12-17       Impact factor: 12.300

5.  Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.

Authors:  Antonietta Arcella; Giulia Carpinelli; Giuseppe Battaglia; Mara D'Onofrio; Filippo Santoro; Richard Teke Ngomba; Valeria Bruno; Paola Casolini; Felice Giangaspero; Ferdinando Nicoletti
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

6.  Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Authors:  J L Blanc; M Wager; J Guilhot; S Kusy; B Bataille; T Chantereau; F Lapierre; C J Larsen; L Karayan-Tapon
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.

Authors:  Huibo Wang; Shu-Yu Zhang; Shuai Wang; Juan Lu; Wenting Wu; Lin Weng; Dan Chen; Yu Zhang; Zhipeng Lu; Jingmin Yang; Yuanyuan Chen; Xu Zhang; Xiaofeng Chen; Caihua Xi; Daru Lu; Shiguang Zhao
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 8.  Pharmacotherapy for adults with tumors of the central nervous system.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2008-11-27       Impact factor: 12.310

9.  Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine.

Authors:  Elvis Terci Valera; Maria Angélica Abdalla de Freitas Cortez; Rosane Gomes de Paula Queiroz; Fabio Morato de Oliveira; María Sol Brassesco; Nada Jabado; Damien Faury; Michael S Bobola; Hélio Rubens Machado; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2008-10-23       Impact factor: 1.475

10.  The combined effects of multiple chemotherapeutic agents for malignant glioma cells.

Authors:  Takao Nakagawa; Toshihiko Kubota; Kazunori Ido; Takahiro Sakuma; Ken Matsuda
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.